Gardasil approved for the prevention of genital warts in boys and young men

The FDA has approved Gardasil (human papillomavirus quadrivalent [types 6, 11, 16, and 18] vaccine, recombinant, from Merck) for the prevention of genital warts caused by human papillomavirus (HPV) types 6 and 11 in boys and young men 9–26 years of age.

Gardasil is already indicated in females 9–26 years old, to prevent cervical, vulvar, and vaginal cancer caused by HPV types 16 and 18; genital warts caused by HPV types 6 and 11; cervical adenocarcinoma in situ (AIS) and cervical intraepithelial neoplasia (CIN) grades 2 and 3, vulvar intraepithelial neoplasia (VIN) grades 2 and 3, vaginal intraepithelial neoplasia (VaIN) grades 2 and 3, and cervical intraepithelial neoplasia (CIN) grade 1 caused by HPV types 6, 11, 16, and 18.

For more information call (800) 672-6372 or visit www.gardasil.com.